FR2705686B1 - New defective adenoviruses and corresponding complementation lines. - Google Patents

New defective adenoviruses and corresponding complementation lines.

Info

Publication number
FR2705686B1
FR2705686B1 FR9306482A FR9306482A FR2705686B1 FR 2705686 B1 FR2705686 B1 FR 2705686B1 FR 9306482 A FR9306482 A FR 9306482A FR 9306482 A FR9306482 A FR 9306482A FR 2705686 B1 FR2705686 B1 FR 2705686B1
Authority
FR
France
Prior art keywords
adenovirus
region
lack
derived
those
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR9306482A
Other languages
French (fr)
Other versions
FR2705686A1 (en
Inventor
Imler Jean-Luc
Methali Majid
Pavirani Andrea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9447589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2705686(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transgene SA filed Critical Transgene SA
Priority to FR9306482A priority Critical patent/FR2705686B1/en
Priority to PT98124039T priority patent/PT919627E/en
Priority to PCT/FR1994/000624 priority patent/WO1994028152A1/en
Priority to US08/379,452 priority patent/US6040174A/en
Priority to AT94917063T priority patent/ATE199262T1/en
Priority to DE69426722T priority patent/DE69426722T2/en
Priority to AT98124039T priority patent/ATE196502T1/en
Priority to EP98124038A priority patent/EP0919626A3/en
Priority to JP50031795A priority patent/JP4226071B2/en
Priority to EP94917063A priority patent/EP0652968B1/en
Priority to ES98124037T priority patent/ES2182212T3/en
Priority to EP98124037A priority patent/EP0919625B1/en
Priority to EP98124036A priority patent/EP0919624A3/en
Priority to ES98124039T priority patent/ES2151310T5/en
Priority to ES94917063T priority patent/ES2155090T3/en
Priority to PT98124037T priority patent/PT919625E/en
Priority to EP98124039A priority patent/EP0919627B2/en
Priority to DE0919627T priority patent/DE919627T1/en
Priority to CA002141212A priority patent/CA2141212C/en
Priority to AT98124037T priority patent/ATE223968T1/en
Priority to DK94917063T priority patent/DK0652968T3/en
Priority to DK98124039T priority patent/DK0919627T4/en
Priority to DE69431372T priority patent/DE69431372T2/en
Priority to DK98124037T priority patent/DK0919625T3/en
Priority to DE69425989T priority patent/DE69425989T3/en
Priority to PT94917063T priority patent/PT652968E/en
Priority to SG1996009706A priority patent/SG55199A1/en
Priority to AU68503/94A priority patent/AU6850394A/en
Priority to EP01111931A priority patent/EP1149916A3/en
Publication of FR2705686A1 publication Critical patent/FR2705686A1/en
Application granted granted Critical
Publication of FR2705686B1 publication Critical patent/FR2705686B1/en
Priority to AU56251/98A priority patent/AU710962B2/en
Priority to US09/409,670 priority patent/US6133028A/en
Priority to GR20000402659T priority patent/GR3034956T3/en
Priority to US09/725,720 priority patent/US7005277B2/en
Priority to US09/739,007 priority patent/US7067309B2/en
Priority to GR20010400689T priority patent/GR3035841T3/en
Priority to JP2008248884A priority patent/JP5410721B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Abstract

New replication-defective adenoviruses are selected from: (a) those that are derived from a natural adenovirus and lack at least the coding sequences of the E1B region and/or at least part of the E4 region; (b) those that are derived from a natural adenovirus other than a human type 5 adenovirus (Ad5) and lack part of the encapsidation region; (c) those that are derived from Ad5 and lack the part of the encapsidation region corresp. to nucleotides 270-346 in the Genbank M73260 sequence; and (d) those that are derived from Ad5 and lack the part of the encapsidation region corresp. to nucleotides 184-273 in the Genbank M73260 sequence. Also claimed is a eukaryotic cell contg. an adenovirus as above. Also claimed are: (1) a complementation line comprising a cell line contg. a complementation element which comprises at least part of the E1 region of a natural adenovirus and lacks the 5' ITR sequence, the element being integrated into the genome or inserted into a vector: and (2) a process for producing a defective adenovirus as above, comprising introducing the virus into a complementation line as above, culturing the cell line, and recovering the virus from the culture supernatant.
FR9306482A 1993-05-28 1993-05-28 New defective adenoviruses and corresponding complementation lines. Expired - Lifetime FR2705686B1 (en)

Priority Applications (36)

Application Number Priority Date Filing Date Title
FR9306482A FR2705686B1 (en) 1993-05-28 1993-05-28 New defective adenoviruses and corresponding complementation lines.
DK98124039T DK0919627T4 (en) 1993-05-28 1994-05-27 Newcomer complement cell lines for defective adenoviruses
DK94917063T DK0652968T3 (en) 1993-05-28 1994-05-27 Defective adenovirus
US08/379,452 US6040174A (en) 1993-05-28 1994-05-27 Defective adenoviruses and corresponding complementation lines
AT94917063T ATE199262T1 (en) 1993-05-28 1994-05-27 DEFECTIVE ADENOVIRUSES
DE69426722T DE69426722T2 (en) 1993-05-28 1994-05-27 DEFECTIVE ADENOVIRUS
AT98124039T ATE196502T1 (en) 1993-05-28 1994-05-27 NEW COMPLEMENTATION CELL LINES FOR DEFECTIVE ADENOVIRAL VECTORS
AT98124037T ATE223968T1 (en) 1993-05-28 1994-05-27 DEFECTIVE ADENOVIRUSES
JP50031795A JP4226071B2 (en) 1993-05-28 1994-05-27 Defective adenovirus and corresponding supplementary systems
EP94917063A EP0652968B1 (en) 1993-05-28 1994-05-27 Defective adenoviruses
ES98124037T ES2182212T3 (en) 1993-05-28 1994-05-27 DEFECTIVE ADENOVIRUS.
EP98124037A EP0919625B1 (en) 1993-05-28 1994-05-27 Defective Adenoviruses
EP98124036A EP0919624A3 (en) 1993-05-28 1994-05-27 Defective Adenoviruses and corresponding transcomplementant celllines
ES98124039T ES2151310T5 (en) 1993-05-28 1994-05-27 NEW DEFECTIVE ADENOVIRAL VECTORS AND CORRESPONDING COMPLEMENTATION CELL LINES.
ES94917063T ES2155090T3 (en) 1993-05-28 1994-05-27 DEFECTIVE ADENOVIRUS.
PT98124037T PT919625E (en) 1993-05-28 1994-05-27 DEFECTIVE ADENOVIRUS
PCT/FR1994/000624 WO1994028152A1 (en) 1993-05-28 1994-05-27 Defective adenoviruses and corresponding complementation lines
DE0919627T DE919627T1 (en) 1993-05-28 1994-05-27 Defective adenoviruses and corresponding transcomplementant cell lines
PT98124039T PT919627E (en) 1993-05-28 1994-05-27 NEW CELLULAR LINES OF COMPLEMENTATION FOR DEFECTIVE ADENOVARY VECTORS
EP98124038A EP0919626A3 (en) 1993-05-28 1994-05-27 Defective Adenoviruses and corresponding transcomplementant celllines
EP98124039A EP0919627B2 (en) 1993-05-28 1994-05-27 New defective adenovirus and corresponding transcomplementing celllines
CA002141212A CA2141212C (en) 1993-05-28 1994-05-27 Defective adenovirus and corresponding complementation lines
DE69431372T DE69431372T2 (en) 1993-05-28 1994-05-27 Defective adenoviruses
DK98124037T DK0919625T3 (en) 1993-05-28 1994-05-27 Defective adenovirus
DE69425989T DE69425989T3 (en) 1993-05-28 1994-05-27 New complementation cell lines for defective adenoviral vectors
PT94917063T PT652968E (en) 1993-05-28 1994-05-27 DEFECTIVE ADENOVIRUS
SG1996009706A SG55199A1 (en) 1993-05-28 1994-05-27 Defective adenoviruses and corresponding complementation lines
AU68503/94A AU6850394A (en) 1993-05-28 1994-05-27 Defective adenoviruses and corresponding complementation lines
EP01111931A EP1149916A3 (en) 1993-05-28 1994-05-27 Defective Adenoviruses and corresponding transcomplementant cell lines
AU56251/98A AU710962B2 (en) 1993-05-28 1998-02-23 Defective adenoviruses and corresponding complementation lines
US09/409,670 US6133028A (en) 1993-05-28 1999-09-30 Defective adenoviruses and corresponding complementation lines
US09/725,720 US7005277B2 (en) 1993-05-28 2000-11-30 Defective adenoviruses and corresponding complementation lines
GR20000402659T GR3034956T3 (en) 1993-05-28 2000-11-30 Defective Adenoviruses and corresponding transcomplementant celllines
US09/739,007 US7067309B2 (en) 1993-05-28 2000-12-19 Defective adenoviruses and corresponding complementation lines
GR20010400689T GR3035841T3 (en) 1993-05-28 2001-05-09 Defective adenoviruses and corresponding complementation lines.
JP2008248884A JP5410721B2 (en) 1993-05-28 2008-09-26 Defective adenovirus and corresponding supplementary systems

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9306482A FR2705686B1 (en) 1993-05-28 1993-05-28 New defective adenoviruses and corresponding complementation lines.

Publications (2)

Publication Number Publication Date
FR2705686A1 FR2705686A1 (en) 1994-12-02
FR2705686B1 true FR2705686B1 (en) 1995-08-18

Family

ID=9447589

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9306482A Expired - Lifetime FR2705686B1 (en) 1993-05-28 1993-05-28 New defective adenoviruses and corresponding complementation lines.

Country Status (14)

Country Link
US (3) US6040174A (en)
EP (6) EP0919624A3 (en)
JP (2) JP4226071B2 (en)
AT (3) ATE223968T1 (en)
AU (1) AU6850394A (en)
CA (1) CA2141212C (en)
DE (4) DE919627T1 (en)
DK (3) DK0919627T4 (en)
ES (3) ES2155090T3 (en)
FR (1) FR2705686B1 (en)
GR (2) GR3034956T3 (en)
PT (3) PT652968E (en)
SG (1) SG55199A1 (en)
WO (1) WO1994028152A1 (en)

Families Citing this family (310)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
EP0911413A3 (en) * 1992-12-03 2000-11-15 Genzyme Corporation Minimal adenovirus-based gene therapy vector
JPH09500782A (en) * 1993-04-08 1997-01-28 ジェネティック セラピー，インコーポレイテッド Adenovirus vector containing DNA encoding lung surfactant protein
US6133028A (en) * 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2705686B1 (en) 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
EP0710288B1 (en) * 1993-06-10 2006-04-05 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
US20020136708A1 (en) 1993-06-24 2002-09-26 Graham Frank L. System for production of helper dependent adenovirus vectors based on use of endonucleases
AU7264694A (en) * 1993-07-13 1995-02-13 Rhone-Poulenc Rorer S.A. Defective adenovirus vectors and use thereof in gene therapy
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US6057299A (en) * 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
US5698443A (en) * 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
ATE272113T1 (en) * 1994-02-16 2004-08-15 Crucell Holland Bv MELANOMA-ASSOCIATED ANTIGENS, EPITOPES THEREOF AND VACCINES AGAINST MELANOMA
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
EP0763103A4 (en) * 1994-04-28 1998-07-15 Univ Michigan Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line
US6451571B1 (en) 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
JP3816518B2 (en) * 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド Complementary adenoviral vector systems and cell lines
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
ATE246252T1 (en) 1994-08-16 2003-08-15 Crucell Holland Bv ADENOVIRUS-DERIVED RECOMBINANT VECTORS FOR GENE THERAPY
FR2725213B1 (en) * 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa VIRAL VECTORS AND USE IN GENE THERAPY
FR2725726B1 (en) * 1994-10-17 1997-01-03 Centre Nat Rech Scient VIRAL VECTORS AND USE IN GENE THERAPY
ES2240980T3 (en) * 1994-10-28 2005-10-16 The Trustees Of The University Of Pennsylvania ADENOVIRUS IMPROVED AND METHODS OF USING THE SAME.
FR2726285B1 (en) 1994-10-28 1996-11-29 Centre Nat Rech Scient ADENOVIRUSES CONTAINING VIABLE CONTAMINANT PARTICLES, PREPARATION AND USE
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
AU709498B2 (en) * 1994-12-12 1999-09-02 Genetic Therapy, Inc. Improved adenoviral vectors and producer cells
FR2741891B1 (en) * 1995-06-01 1998-01-09 Centre Nat Rech Scient CELLS FOR THE PRODUCTION OF RECOMBINANT ADENOVIRUSES
FR2738575B1 (en) * 1995-09-08 1997-10-10 Centre Nat Rech Scient CELLS FOR THE PRODUCTION OF RECOMBINANT ADENOVIRUSES
FR2729674B1 (en) * 1995-01-20 1997-04-11 Centre Nat Rech Scient CELLS FOR THE PRODUCTION OF RECOMBINANT ADENOVIRUSES
IL116816A (en) * 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
FR2730411B1 (en) * 1995-02-14 1997-03-28 Centre Nat Rech Scient DRUG ASSOCIATION USEFUL FOR IN VIVO TRANSFECTION AND EXPRESSION OF EXOGENES
US6251957B1 (en) 1995-02-24 2001-06-26 Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
US6372208B1 (en) 1999-09-28 2002-04-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
FR2731710B1 (en) * 1995-03-14 1997-04-30 Rhone Poulenc Rorer Sa RECOMBINANT VIRUSES EXPRESSING LECITHIN CHOLESTEROL ACYLTRANSFERASE AND USES IN GENE THERAPY
JP3770333B2 (en) * 1995-03-15 2006-04-26 大日本住友製薬株式会社 Recombinant DNA virus and method for producing the same
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
FR2732357B1 (en) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa VIRAL VECTORS AND USE FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS, ESPECIALLY RESTENOSIS
JPH11503910A (en) * 1995-04-17 1999-04-06 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Adenovirus helper virus system
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US6019978A (en) 1995-06-05 2000-02-01 The Wistar Institute Of Anatomy And Biology Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
US5698202A (en) * 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
US5985846A (en) * 1995-06-07 1999-11-16 Baylor College Of Medicine Gene therapy for muscular dystrophy
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
ES2333425T5 (en) 1995-06-15 2012-08-28 Crucell Holland B.V. Packaging systems for human recombinant adenovirus intended for gene therapy
FR2735789B1 (en) 1995-06-23 1997-07-25 Centre Nat Rech Scient RECOMBINANT ADENOVIRUSES, THEIR USE FOR PREPARING AVA, COMPLEMENTARY CELL LINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6676935B2 (en) 1995-06-27 2004-01-13 Cell Genesys, Inc. Tissue specific adenoviral vectors
CZ15498A3 (en) 1995-07-17 1998-07-15 Board Of Regents, The University Of Texas System STRUCTURE FOR EXPRESSION OF p16 AND ITS APPLICATION WHEN TREATING CANCER
US7163925B1 (en) 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
FR2737222B1 (en) * 1995-07-24 1997-10-17 Transgene Sa NEW VIRAL AND LINEAR VECTORS FOR GENE THERAPY
FR2737221B1 (en) * 1995-07-24 1997-10-17 Transgene Sa NEW VIRAL VECTORS FOR GENE THERAPY
US6261554B1 (en) 1995-07-25 2001-07-17 Introgene B.V. Compositions for targeted gene delivery
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US6004797A (en) * 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
JP2006075171A (en) * 1995-11-09 2006-03-23 Avigen Inc Accessory functions for use in recombinant aav virion production
US5891690A (en) * 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
CA2257148A1 (en) * 1996-05-31 1997-12-04 Wei-Wei Zhang Mini-adenoviral vector
FR2750433B1 (en) * 1996-07-01 1998-08-14 Rhone Poulenc Rorer Sa PROCESS FOR PRODUCING RECOMBINANT ADENOVIRUSES
EP0944717A1 (en) * 1996-07-01 1999-09-29 Aventis Pharma S.A. Method for producing recombinant adenovirus
US20040156861A1 (en) * 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
JP4615634B2 (en) 1996-12-06 2011-01-19 アベンティス・ファーマスーティカルズ・インコーポレイテツド Triacylglycerol lipase family LLG polypeptides, compositions, methods for use in enzymatic hydrolysis, protein and gene therapy
US7008776B1 (en) 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
WO1998037185A2 (en) * 1997-02-20 1998-08-27 The Board Of Regents Of The University Of Texas System Vectors for controlled gene expression
FR2761689B1 (en) 1997-04-02 1999-06-25 Transgene Sa MODIFIED ADENOVIRAL FIBER AND TARGET ADENOVIRUS
KR20010020342A (en) 1997-04-28 2001-03-15 자끄 사비나 Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
US5849561A (en) * 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
WO1998054345A1 (en) * 1997-05-30 1998-12-03 Baxter International Inc. Mini-adenoviral vector
FR2766091A1 (en) 1997-07-18 1999-01-22 Transgene Sa ANTITUMOR COMPOSITION BASED ON MODIFIED IMMUNOGENIC POLYPEPTIDE WITH CELL LOCATION
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US6653088B1 (en) 1997-10-24 2003-11-25 Aventis Pharma S.A. Interaction test for the investigation of inhibitory molecules of the interaction between a presenilin and the β-amyloid peptide
NZ504214A (en) * 1997-10-24 2003-06-30 Invitrogen Corp Recombination cloning using nucleic acids having recombination sites
EP1029052B1 (en) 1997-11-06 2010-08-04 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigens
EP1049767B1 (en) 1998-01-08 2005-08-17 Aventis Pharmaceuticals Inc. A transgenic rabbit that expresses a functional human lipoprotein (a)
DE69941567D1 (en) 1998-01-14 2009-12-03 Novartis Vaccines & Diagnostic ANTIGENE FROM NEISSERIA MENINGITIDIS
US6803194B1 (en) 1998-02-13 2004-10-12 Hk Pharmaceuticals, Inc. Use of ribozymes for functionating genes
US5981225A (en) * 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
ES2294629T3 (en) 1998-05-01 2008-04-01 Novartis Vaccines And Diagnostics, Inc. ANTIGENS OF NEISSERIA AND COMPOSITIONS.
US6225456B1 (en) 1998-05-07 2001-05-01 University Technololy Corporation Ras suppressor SUR-5
US6506889B1 (en) 1998-05-19 2003-01-14 University Technology Corporation Ras suppressor SUR-8 and related compositions and methods
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US6328958B1 (en) 1998-08-28 2001-12-11 Duke University Deleted adenovirus vectors and methods of making and administering the same
DE19856065A1 (en) * 1998-12-04 2000-06-15 Centeon Pharma Gmbh Recombinant, adenoviral vector with limited auto-replication ability in vivo
US6225113B1 (en) 1998-12-04 2001-05-01 Genvec, Inc. Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
FR2787465A1 (en) 1998-12-21 2000-06-23 Transgene Sa PROCESS FOR INACTIVATION OF ENVELOPED VIRUSES IN VIRUS PREPARATION OF NON-ENVELOPED VIRUSES
US6441156B1 (en) 1998-12-30 2002-08-27 The United States Of America As Represented By The Department Of Health And Human Services Calcium channel compositions and methods of use thereof
EP1016726A1 (en) * 1998-12-30 2000-07-05 Introgene B.V. Gene therapy to promote angiogenesis
CA2363061A1 (en) * 1999-02-18 2000-08-24 Merck & Co., Inc. Production of helper dependent adenovirus vectors based on use of endonucleases
ES2162551B1 (en) * 1999-04-09 2002-07-01 Univ Madrid Autonoma PROCEDURE FOR THE SELECTIVE REPLICATION OF DEFECTIVE ADENOVIRUS IN TUMOR CELLS.
US6490775B1 (en) * 1999-04-23 2002-12-10 Veri-Tek Inc. Press operation verification system
ES2397918T3 (en) 1999-04-30 2013-03-12 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens conserved
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
US7226786B2 (en) * 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
FR2794771B1 (en) 1999-06-11 2001-08-10 Aventis Pharma Sa RECOMBINANT ADENOVIRUSES ENCODING THE IODINE SPECIFIC TRANSPORTER (NIS)
EP1200622A4 (en) * 1999-07-06 2004-12-22 Merck & Co Inc Adenovirus carrying gag gene hiv vaccine
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
FR2799472B1 (en) * 1999-10-07 2004-07-16 Aventis Pharma Sa PREPARATION OF RECOMBINANT ADENOVIRUSES AND ADENOVIRAL BANKS
ES2564463T3 (en) 1999-10-29 2016-03-22 Glaxosmithkline Biologicals S.A. Neisserial antigenic peptides
CN1254719A (en) * 1999-11-19 2000-05-31 钱其军 Defective adenovirus and its building-up method
US6558948B1 (en) 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
PT2289545T (en) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Supplemented omv vaccine against meningococcus
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
KR100811571B1 (en) 2000-03-31 2008-03-10 아벤티스 파마슈티칼스 인크. Nuclear factor ?B inducing factor
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
EP1167533A1 (en) * 2000-06-23 2002-01-02 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Methods and means for the complementation of viral protein expression in stable cell lines
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
EP1320621A4 (en) * 2000-09-15 2005-11-23 Merck & Co Inc Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
US20040101957A1 (en) * 2001-09-14 2004-05-27 Emini Emilio A. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications
US6733993B2 (en) * 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
US6916635B2 (en) * 2000-10-02 2005-07-12 The Research Foundation Of State University Of New York Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
EP2284182A1 (en) 2000-10-27 2011-02-16 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A and B
US7060442B2 (en) 2000-10-30 2006-06-13 Regents Of The University Of Michigan Modulators on Nod2 signaling
JP2002142770A (en) * 2000-11-08 2002-05-21 Dnavec Research Inc Paramyxovirus vector for transporting gene to circulatory system
KR20030074680A (en) 2000-12-28 2003-09-19 와이어쓰 Recombinant protective protein from $i(streptococcus pneumoniae)
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
AUPR518501A0 (en) 2001-05-22 2001-06-14 Unisearch Limited Yin yang-1
US6682929B2 (en) 2001-07-23 2004-01-27 Genvec, Inc. Adenovector complementing cells
US6677156B2 (en) 2001-07-23 2004-01-13 Genvec, Inc. Non-adenoviral gene product-based complementing cells for adenoviral vectors
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
EP2335723A1 (en) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia trachomatis
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
DK1497440T3 (en) * 2002-04-25 2008-12-01 Crucell Holland Bv Stable adenoviral vectors and methods of propagation thereof
EP1504766A4 (en) * 2002-04-30 2006-11-02 Dnavec Research Inc Drug- or gene-carrier composition having lowered hemagglutinin activity
PL210412B1 (en) 2002-05-24 2012-01-31 Schering Corp Neutralizing human anti-igfr antibody
US20040219516A1 (en) * 2002-07-18 2004-11-04 Invitrogen Corporation Viral vectors containing recombination sites
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
CA2421269A1 (en) 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US20040052161A1 (en) * 2002-09-17 2004-03-18 Steven Liao Mechanical clock having wireless manipulation and adjustment function
CA2503317A1 (en) * 2002-10-24 2004-05-06 Dnavec Research Inc. Method of transferring gene into t cells
AU2003295502A1 (en) 2002-11-12 2004-06-03 Yucheng Chang Adenoviral vector vaccine
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
EP1642966B1 (en) * 2003-06-30 2010-03-03 Dnavec Research Inc. Minus strand rna viral vectors carrying a gene with altered hypermutable regions
CN103484485B (en) * 2003-07-02 2017-08-15 Bp法人北美有限公司 Dextranase, encode they nucleic acid and preparation and use their method
US7026164B2 (en) * 2003-07-03 2006-04-11 Cell Genesys, Inc. Adenovirus packaging cell lines
KR101062140B1 (en) 2003-07-21 2011-09-05 트랜스진 에스.에이. Polypeptides with Enhanced Cytosine Deminase Activity
DK1944318T3 (en) 2003-07-21 2011-06-14 Transgene Sa Multifunctional cytokines
WO2005051991A2 (en) 2003-11-24 2005-06-09 Sidney Kimmel Cancer Center Mucin antigen vaccine
EP1697534B1 (en) 2003-12-01 2010-06-02 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same
US8828957B2 (en) * 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
WO2005058369A2 (en) * 2003-12-15 2005-06-30 The University Of Iowa Research Foundation Compositions of l-caldesmon for treating viral infection
JPWO2005071085A1 (en) * 2004-01-22 2007-09-06 株式会社ディナベック研究所 Method for producing viral vector
US7432057B2 (en) 2004-01-30 2008-10-07 Michigan State University Genetic test for PSE-susceptible turkeys
EP1780269B1 (en) * 2004-02-23 2009-07-08 Crucell Holland B.V. Virus purification methods
CN104292321A (en) 2004-03-29 2015-01-21 株式会社嘉尔药物 Novel modified galectin 9 protein and use thereof
CA2563396A1 (en) 2004-04-12 2005-11-24 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Method of using adenoviral vectors to induce an immune response
US7604798B2 (en) 2004-07-15 2009-10-20 Northwestern University Methods and compositions for importing nucleic acids into cell nuclei
US20090214588A1 (en) 2004-07-16 2009-08-27 Nabel Gary J Vaccines against aids comprising cmv/r-nucleic acid constructs
CN101027662A (en) * 2004-08-04 2007-08-29 阿菲克姆智能牧场管理系统公司 A method and a system for locating objects in a defined area
AU2006336468B2 (en) 2005-02-11 2012-04-12 University Of Southern California Method of expressing proteins with disulfide bridges
DK1869171T4 (en) * 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
EP2002003B1 (en) 2005-05-27 2015-12-30 Ospedale San Raffaele S.r.l. Gene vector comprising mi-rna
WO2006130525A2 (en) * 2005-05-31 2006-12-07 Sidney Kimmel Cancer Center Methods for immunotherapy of cancer
US8765146B2 (en) 2005-08-31 2014-07-01 Genvec, Inc. Adenoviral vector-based malaria vaccines
US8716021B2 (en) * 2005-09-07 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of replicators to prevent gene silencing
PT1950307E (en) * 2005-10-28 2016-02-29 Ip Pharma Co Ltd Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with rna virus spike protein
JP2009514536A (en) * 2005-11-07 2009-04-09 シドニー キンメル キャンサー センター CD40 ligand fusion protein vaccine
WO2007059461A2 (en) 2005-11-10 2007-05-24 Genvec, Inc. Adenoviral vector-based foot-and-mouth disease vaccine
WO2007130501A2 (en) * 2006-05-01 2007-11-15 University Of Southern California Combination therapy for treatment of cancer
PL2054431T3 (en) 2006-06-09 2012-07-31 Novartis Ag Conformers of bacterial adhesins
EP2049666A2 (en) 2006-07-28 2009-04-22 Sanofi-Aventis Composition and method for treatment of tumors
PL2068922T3 (en) 2006-10-19 2012-11-30 Csl Ltd Anti-il-13r alpha 1 antibodies and their uses thereof
AU2007319604B2 (en) 2006-10-19 2011-03-24 Csl Limited High affinity antibody antagonists of interleukin-13 receptor alpha 1
AR064642A1 (en) 2006-12-22 2009-04-15 Wyeth Corp POLINUCLEOTIDE VECTOR THAT INCLUDES IT RECOMBINATING CELL THAT UNDERSTANDS THE VECTOR POLYPEPTIDE, ANTIBODY, COMPOSITION THAT UNDERSTANDS THE POLINUCLEOTIDE, VECTOR, RECOMBINATING CELL POLYPEPTIDE OR ANTIBODY, USE OF THE COMPOSITION AND A COMPOSITION AND A METHOD
PL2118292T3 (en) 2007-01-30 2011-12-30 Transgene Sa Papillomavirus e2 polypeptide used for vaccination
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
ES2337973B8 (en) 2008-05-16 2011-07-21 Proyecto De Biomedicina Cima, S.L. ADENOVIRUS AUXILIARY SELF-INACTIVANTS FOR THE PRODUCTION OF ADENOVIRUS RECOMBINANTS OF HIGH CAPACITY.
MX2011004292A (en) * 2008-11-03 2011-05-31 Crucell Holland Bv Method for the production of adenoviral vectors.
RU2478396C2 (en) 2008-11-05 2013-04-10 ВАЙЕТ ЭлЭлСи MULTI-COMPONENT IMMUNOGENIC COMPOSITION FOR PREVENTING DOSEASE, CAUSED BY β-HEMOLYTIC STREPTOCCOCI (BHS)
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
AU2010205717A1 (en) 2009-01-13 2010-07-22 Transgene Sa Use of a Saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation
JP5379243B2 (en) 2009-01-20 2013-12-25 トランジェーヌ、ソシエテ、アノニム Biomarkers and related methods for selecting patients
WO2010096561A1 (en) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
SG174507A1 (en) 2009-03-24 2011-10-28 Transgene Sa Biomarker for monitoring patients
JP5661738B2 (en) 2009-04-17 2015-01-28 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． Biomarkers for monitoring patients
NZ596325A (en) 2009-07-10 2013-11-29 Transgene Sa Biomarker for selecting patients and related methods
RU2555346C2 (en) 2009-08-07 2015-07-10 Трансген Са Composition for treating hepatitis b virus infections
EP2488635B1 (en) 2009-10-15 2013-11-20 Crucell Holland B.V. Process for adenovirus purification from high cell density cultures
CN102791852B (en) 2009-10-15 2014-05-07 克鲁塞尔荷兰公司 Method for the purification of adenovirus particles
WO2011047316A1 (en) 2009-10-16 2011-04-21 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Nucleic acid sequences encoding expandable hiv mosaic proteins
US9133248B2 (en) 2009-11-09 2015-09-15 Genvec, Inc. Methods of propagating monkey adenoviral vectors
WO2011057254A2 (en) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
JP5250155B2 (en) 2010-02-15 2013-07-31 クルセル ホランド ベー ヴェー Method for producing Ad26 adenovirus vector
CN102892429B (en) 2010-03-17 2016-08-31 康奈尔大学 Abuse resistant drugs vaccine based on destroyed adenovirus
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
ES2864635T3 (en) 2010-09-10 2021-10-14 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
CA2808556A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
CA2809463C (en) 2010-09-27 2021-05-25 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
US8920813B2 (en) 2010-12-20 2014-12-30 Genvec, Inc. Adenoviral vector-based dengue fever vaccine
ES2640113T3 (en) 2011-02-08 2017-10-31 Mie University Method to produce a viral vector for gene transfer
US9796973B2 (en) 2011-04-28 2017-10-24 Yamaguchi University Terminator sequence-containing reverse primer for overexpression and linear DNA
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
TWI575070B (en) 2011-07-12 2017-03-21 傳斯堅公司 Hbv polymerase mutants
WO2013045668A2 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
WO2013045658A1 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
CA2850627A1 (en) 2011-10-05 2013-04-11 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
BR112014008284A2 (en) 2011-10-05 2020-10-27 Genvec Inc. simian adenovirus (gorilla) or adenoviral vectors and methods of use
EP2764012B1 (en) 2011-10-05 2022-02-23 GenVec, Inc. Adenoviral vectors and methods of use
WO2013052859A2 (en) 2011-10-05 2013-04-11 Genvec, Inc. Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
WO2013116591A1 (en) 2012-02-02 2013-08-08 Genvec, Inc. Adenoviral vector-based malaria vaccine
SA115360586B1 (en) 2012-03-09 2017-04-12 فايزر انك Neisseria meningitidis compositions and methods thereof
EP2822583A2 (en) 2012-03-09 2015-01-14 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP2825640B1 (en) 2012-03-12 2016-04-27 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
EA026504B1 (en) 2012-03-22 2017-04-28 Круселл Холланд Б.В. Vaccine against rsv
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
WO2013181128A1 (en) 2012-05-29 2013-12-05 Genvec, Inc. Modified serotype 28 adenoviral vectors
WO2013180967A1 (en) 2012-05-29 2013-12-05 Genvec, Inc. Herpes simplex virus vaccine
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
CN104640564B (en) 2012-07-10 2020-08-04 特兰斯吉恩股份有限公司 Mycobacterial antigen vaccines
EP3587455A1 (en) 2012-10-23 2020-01-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
JP6446377B2 (en) 2013-03-08 2018-12-26 ファイザー・インク Immunogenic fusion polypeptide
EP2968613B1 (en) 2013-03-11 2019-09-11 University of Florida Research Foundation, Inc. Delivery of card protein as therapy for occular inflammation
ME03442B (en) 2013-04-25 2020-01-20 Janssen Vaccines & Prevention Bv Stabilized soluble prefusion rsv f polypeptides
US10294279B2 (en) 2013-06-17 2019-05-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
CN105492021B (en) 2013-09-08 2018-12-04 辉瑞公司 Neisseria meningitidis composition and its method
NZ717156A (en) 2013-09-19 2022-04-29 Janssen Vaccines & Prevention Bv Improved adenovirus formulations
BR112016015936A2 (en) 2014-01-09 2017-09-19 Transgene Sa IMMUNOGENIC COMBINATION, NUCLEIC ACID MOLECULE, VECTOR, HOST CELL, RECOMBINANT ANTIGENS PRODUCTION METHOD AND COMPOSITION
WO2015127094A1 (en) 2014-02-19 2015-08-27 University Of Florida Research Foundation, Inc. Delivery of nrf2 as therapy for protection against reactive oxygen species
WO2016037154A1 (en) 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant hiv-1 envelope proteins and their use
EP3421046A1 (en) 2014-11-04 2019-01-02 Janssen Vaccines & Prevention B.V. Therapeutic hpv16 vaccines
EP3236998A1 (en) 2014-12-24 2017-11-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Recombinant metapneumovirus f proteins and their use
WO2016118642A1 (en) 2015-01-20 2016-07-28 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant human/bovine parainfluenza virus 3 (b/hpiv3) expressing a chimeric rsv/bpiv3 f protein and uses thereof
MX2017010705A (en) 2015-02-19 2017-12-04 Pfizer Neisseria meningitidis compositions and methods thereof.
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
KR20170140180A (en) 2015-02-24 2017-12-20 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
JP6887955B2 (en) 2015-03-18 2021-06-16 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Recombinant expression system assay
JP6960396B2 (en) 2015-04-07 2021-11-05 ザ ジェイ． デビッド グラッドストーン インスティテューツ、 ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デビッド グラッドストーン Methods for Inducing Cell Division in End-Division Cells
EP3283634B1 (en) 2015-04-14 2019-05-22 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
IL288541B (en) 2015-07-07 2022-08-01 Janssen Vaccines Prevention B V Vaccine against rsv
EA037295B1 (en) 2015-08-20 2021-03-05 Янссен Вэксинс Энд Превеншн Б.В. Therapeutic hpv18 vaccines
CN108135843B (en) 2015-10-06 2021-11-02 扬森疫苗与预防公司 Method for preventing plastic-induced degradation of biologicals
WO2017139392A1 (en) 2016-02-08 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant hiv-1 envelope proteins and their use
WO2017156272A1 (en) 2016-03-09 2017-09-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant hiv-1 envelope proteins and their use
SG11201807912SA (en) 2016-04-05 2018-10-30 Janssen Vaccines & Prevention Bv Vaccine against rsv
MA52910A (en) 2016-04-05 2021-04-21 Janssen Vaccines & Prevention Bv PRE-FUSION PROTEIN F OF RSV SOLUBLE AND STABILIZED FOR USE IN THE PROPHYLAXIS OF RSV INFECTION
CA3021341A1 (en) 2016-05-02 2017-11-09 Janssen Vaccine & Prevention B.V. Therapeutic hpv vaccine combinations
WO2017191147A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
ES2829272T3 (en) 2016-05-12 2021-05-31 Janssen Vaccines & Prevention Bv Powerful and balanced bidirectional promoter
EP3464331B1 (en) 2016-05-30 2020-10-28 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
RU2745500C2 (en) 2016-06-20 2021-03-25 Янссен Вэксинс Энд Превеншн Б.В. Efficient and balanced bidirectional promotor
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
CA3038968A1 (en) 2016-09-30 2018-04-05 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into t cells
EP3518968B1 (en) 2016-10-03 2022-01-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Hiv-1 env fusion peptide immunogens and their use
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018081318A1 (en) 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
CN110418650A (en) 2016-11-16 2019-11-05 免疫治疗有限公司 For treating the nucleic acid of allergy
EP3554538A2 (en) 2016-12-16 2019-10-23 Institute for Research in Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
IL303108B1 (en) 2017-01-31 2024-03-01 Pfizer Neisseria meningitidis compositions and methods thereof
MX2019009316A (en) 2017-02-09 2019-09-19 Janssen Vaccines & Prevention Bv Potent and short promoter for expression of heterologous genes.
EP3600405A1 (en) 2017-03-24 2020-02-05 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Glycan-masked engineered outer domains of hiv-1 gp120 and their use
BR112019022108A2 (en) 2017-04-22 2020-05-12 Immunomic Therapeutics, Inc. ENHANCED LAMP CONSTRUCTIONS
EP3618854A1 (en) 2017-05-02 2020-03-11 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
JP2020519663A (en) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Methods and compositions for inducing protective immunity against RSV infection
BR112020004143A2 (en) 2017-09-15 2020-09-01 Janssen Vaccines & Prevention B.V. method for the safe induction of immunity against respiratory syncytial virus (rsv)
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
JP2021502060A (en) 2017-10-16 2021-01-28 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Treatment of amyotrophic lateral sclerosis (ALS)
US11136356B2 (en) 2017-10-16 2021-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
KR20200074987A (en) 2017-10-31 2020-06-25 얀센 백신스 앤드 프리벤션 비.브이. Adenovirus and uses thereof
US11459583B2 (en) 2017-10-31 2022-10-04 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
US11872281B2 (en) 2017-10-31 2024-01-16 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
WO2019086466A1 (en) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
HRP20220980T1 (en) 2018-01-23 2022-11-11 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
KR20200128703A (en) 2018-03-06 2020-11-16 프레시전 인코포레이티드 Hepatitis B vaccine and uses thereof
CA3100004A1 (en) 2018-05-15 2019-11-21 Immunomic Therapeutics, Inc. Improved lamp constructs comprising allergens
WO2020010035A1 (en) 2018-07-02 2020-01-09 Voyager Therapeutics, Inc. Cannula system
CA3103963A1 (en) 2018-07-02 2020-01-09 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
US20210340188A1 (en) 2018-10-22 2021-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Recombinant gp120 protein with v1-loop deletion
TW202043256A (en) 2019-01-10 2020-12-01 美商健生生物科技公司 Prostate neoantigens and their uses
JP2022530439A (en) 2019-04-25 2022-06-29 ヤンセン ファッシンズ アンド プリベンション ベーフェー Recombinant influenza antigen
EP3969044A1 (en) 2019-05-15 2022-03-23 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
MX2021013947A (en) 2019-05-15 2021-12-14 Janssen Vaccines & Prevention Bv Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine.
KR20220057578A (en) 2019-09-05 2022-05-09 얀센 백신스 앤드 프리벤션 비.브이. Influenza virus vaccine and uses thereof
WO2021064688A1 (en) 2019-10-03 2021-04-08 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
JP2022551732A (en) 2019-10-18 2022-12-13 イミュノミック セラピューティックス， インコーポレイテッド Improved LAMP constructs containing cancer antigens
JP2023509571A (en) 2019-11-18 2023-03-09 ヤンセン バイオテツク，インコーポレーテツド Vaccines based on mutant CALR and JAK2 and uses thereof
KR20220140586A (en) 2020-02-11 2022-10-18 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 SARS-CoV-2 vaccine
TW202144388A (en) 2020-02-14 2021-12-01 美商健生生物科技公司 Neoantigens expressed in ovarian cancer and their uses
TW202144389A (en) 2020-02-14 2021-12-01 美商健生生物科技公司 Neoantigens expressed in multiple myeloma and their uses
CN115484978A (en) 2020-03-05 2022-12-16 尼奥克斯医疗有限公司 Methods and compositions for treating cancer using immune cells
US11213482B1 (en) 2020-03-05 2022-01-04 University of Pittsburgh—Of the Commonwealth System of Higher Educat SARS-CoV-2 subunit vaccine and microneedle array delivery system
US11773391B2 (en) 2020-04-01 2023-10-03 University of Pittsburgh—of the Commonwealth System of Higher Education Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19
US20210315986A1 (en) 2020-04-13 2021-10-14 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
EP4142785A2 (en) 2020-04-29 2023-03-08 The United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant human metapneumovirus f proteins and their use
WO2021247995A2 (en) 2020-06-04 2021-12-09 Voyager Therapeutics, Inc. Compositions and methods of treating neuropathic pain
US20230035403A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Method For Determining Responsiveness To Prostate Cancer Treatment
EP4175721A1 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20230256057A1 (en) 2020-07-13 2023-08-17 Transgene Treatment of immune depression
WO2022035860A2 (en) 2020-08-10 2022-02-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Replication-competent adenovirus type 4-hiv env vaccines and their use
WO2022232648A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion-stabilized lassa virus glycoprotein complex and its use
WO2023015186A1 (en) 2021-08-03 2023-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
US20230277600A1 (en) 2021-10-20 2023-09-07 University Of Rochester Treatment Of Age-Related White Matter Loss By Competitive Replacement Of Glial Cells
WO2023081633A1 (en) 2021-11-02 2023-05-11 University Of Rochester Tcf7l2 mediated remyelination in the brain
WO2023091696A1 (en) 2021-11-19 2023-05-25 Christiana Care Gene Editing Institute, Inc. Adenovirus delivery system for cancer treatment
WO2023192835A1 (en) 2022-03-27 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Base-covered hiv-1 envelope ectodomains and their use
WO2023196898A1 (en) 2022-04-07 2023-10-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Beta globin mimetic peptides and their use
WO2023201201A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
EP4338727A1 (en) 2022-09-14 2024-03-20 Roquette Freres Adenovirus formulations

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
GB9001766D0 (en) * 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
GB9114437D0 (en) * 1991-07-03 1991-08-21 Health Lab Service Board Recombinant adenoviruses and the use thereof for detecting the presence in eukaryotic cells of the expression products of specific genes
US6099831A (en) 1992-09-25 2000-08-08 Centre National De La Recherche Scientifique Viral recombinant vectors for expression in muscle cells
FR2681786A1 (en) * 1991-09-27 1993-04-02 Centre Nat Rech Scient RECOMBINANT VECTORS OF VIRAL ORIGIN, PROCESS FOR OBTAINING SAME AND THEIR USE FOR THE EXPRESSION OF POLYPEPTIDES IN MUSCLE CELLS.
FR2688514A1 (en) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
ES2312164T3 (en) * 1992-09-25 2009-02-16 Aventis Pharma S.A. ADENOVIRUS VECTORS FOR THE TRANSFER OF STRANGE GENES IN CELLS OF THE CENTRAL NERVOUS SYSTEM, PARTICULARLY IN THE BRAIN.
JPH08506008A (en) * 1992-11-18 1996-07-02 アーチ ディベロプメント コーポレイション Adenovirus-mediated gene transfer into myocardium and vascular smooth muscle
EP0911413A3 (en) * 1992-12-03 2000-11-15 Genzyme Corporation Minimal adenovirus-based gene therapy vector
JPH09500782A (en) * 1993-04-08 1997-01-28 ジェネティック セラピー，インコーポレイテッド Adenovirus vector containing DNA encoding lung surfactant protein
FR2704234B1 (en) * 1993-04-22 1995-07-21 Centre Nat Rech Scient RECOMBINANT VIRUSES, PREPARATION AND USE IN GENE THERAPY.
FR2704556B1 (en) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Recombinant viruses and their use in gene therapy.
EP1211319A2 (en) * 1993-05-10 2002-06-05 The Regents of The University of Michigan Gene transfer into pancreatic and biliary epithelial cells
FR2705686B1 (en) 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
EP0710288B1 (en) * 1993-06-10 2006-04-05 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
US5543328A (en) 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
JP3816518B2 (en) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド Complementary adenoviral vector systems and cell lines
JP3770333B2 (en) * 1995-03-15 2006-04-26 大日本住友製薬株式会社 Recombinant DNA virus and method for producing the same
ES2333425T5 (en) * 1995-06-15 2012-08-28 Crucell Holland B.V. Packaging systems for human recombinant adenovirus intended for gene therapy
FR2737222B1 (en) 1995-07-24 1997-10-17 Transgene Sa NEW VIRAL AND LINEAR VECTORS FOR GENE THERAPY
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5981275A (en) 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence
US5849561A (en) * 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors

Also Published As

Publication number Publication date
CA2141212A1 (en) 1994-12-08
EP0919625B1 (en) 2002-09-11
EP0919626A3 (en) 1999-08-18
US7067309B2 (en) 2006-06-27
GR3034956T3 (en) 2001-02-28
US20030170885A1 (en) 2003-09-11
JP5410721B2 (en) 2014-02-05
ATE199262T1 (en) 2001-03-15
JP4226071B2 (en) 2009-02-18
DE919627T1 (en) 2000-04-20
DK0652968T3 (en) 2001-06-11
DE69425989D1 (en) 2000-10-26
EP0919625A3 (en) 1999-08-18
EP0919627A3 (en) 1999-07-28
FR2705686A1 (en) 1994-12-02
EP0919624A2 (en) 1999-06-02
EP1149916A2 (en) 2001-10-31
DE69426722D1 (en) 2001-03-29
AU6850394A (en) 1994-12-20
PT919625E (en) 2002-11-29
DE69431372D1 (en) 2002-10-17
ES2151310T5 (en) 2007-10-16
ES2151310T3 (en) 2000-12-16
PT652968E (en) 2001-07-31
EP0652968A1 (en) 1995-05-17
JPH07509616A (en) 1995-10-26
JP2009050267A (en) 2009-03-12
EP0919627A2 (en) 1999-06-02
WO1994028152A1 (en) 1994-12-08
US20010049136A1 (en) 2001-12-06
EP0919627B1 (en) 2000-09-20
DE69425989T2 (en) 2001-02-22
EP0919627B2 (en) 2007-03-14
CA2141212C (en) 2007-04-17
PT919627E (en) 2000-12-29
EP1149916A3 (en) 2007-08-29
EP0652968B1 (en) 2001-02-21
EP0919624A3 (en) 1999-08-18
SG55199A1 (en) 1998-12-21
EP0919626A2 (en) 1999-06-02
DK0919625T3 (en) 2002-12-30
US6040174A (en) 2000-03-21
ES2182212T3 (en) 2003-03-01
DE69425989T3 (en) 2007-10-18
DE69426722T2 (en) 2001-09-20
ATE223968T1 (en) 2002-09-15
ES2155090T3 (en) 2001-05-01
DK0919627T4 (en) 2007-06-25
US7005277B2 (en) 2006-02-28
DE69431372T2 (en) 2003-07-31
ATE196502T1 (en) 2000-10-15
EP0919625A2 (en) 1999-06-02
GR3035841T3 (en) 2001-08-31
DK0919627T3 (en) 2001-01-22

Similar Documents

Publication Publication Date Title
FR2705686B1 (en) New defective adenoviruses and corresponding complementation lines.
Hardy et al. Construction of adenovirus vectors through Cre-lox recombination
Schiedner et al. Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production
McGrory et al. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5
WO2000012740A3 (en) Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences
Zhou et al. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted
WO2005001103A3 (en) Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
WO2000000628A1 (en) Replication-defective recombinant adenovirus with mutated major late promoter
Bhat et al. Adenovirus mutants with DNA sequence perturbations in the intragenic promoter of VAI RNA gene allow the enhanced transcription of VAII RNA gene in HeLa cells
MX9709549A (en) Recombinant adenoviruses, use thereof for preparing aavs, complementary cell line, and pharmaceutical compositions containing said adenoviruses.
CA2161962A1 (en) Adenovirus vectors for gene therapy
CA2047290A1 (en) Recombinant marek's disease virus
Barkner et al. Expression of dihydrololate reductase, and of the adjacent Elb region, in an Ad5-dihydrofolate reductase recombinant virus
CA2226833A1 (en) Adenovirus vectors for gene therapy
Van Ormondt et al. Comparison of the nucleotide sequences of early region Elb DNA of human adenovirus types 12, 7 and 5 (subgroups A, B and C)
Mautner et al. Recombination in adenovirus: DNA sequence analysis of crossover sites in intertypic recombinants
Ito et al. The Expression of Bacteriophage T4 Early Genes: II. Roles of the β′ Subunit of RNA Polymerase and Termination Factor ρ of the Host in the Expression of T4 Early Genes
CA2522624A1 (en) Novel cosmid vector